Figure 3.

STX6 is involved in EMT, cell cycle, and tumor immunity in pan-cancer via gene set enrichment analysis of hallmark gene sets. STX6 expression was favorably connected to the mitotic spindle, G2M checkpoint, and epithelial–mesenchymal transition. Moreover, STX6 was also linked to TNFA signaling via NFKB, IFN-α, IFN-β, and inflammation, as well as allograft-rejection pathways in kidney cancer (KICH, KIRC, and KIRP), CESC, and PAAD; however, this was not the case for other cancers, including LGG, MESO, OV, SARC, SKCM, and STAD, where STX6 inhibits cellular oxidative phosphorylation.